Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.